Get the Stockscreener App
10.20
3.66%
0.36
Aligos Therapeutics Inc stock is traded at $10.20, with a volume of 112.75K.
It is up +3.66% in the last 24 hours and up +11.84% over the past month.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
See More
Previous Close:
$9.84
Open:
$9.88
24h Volume:
112.75K
Relative Volume:
1.16
Market Cap:
$54.58M
Revenue:
$7.97M
Net Income/Loss:
$-75.74M
P/E Ratio:
-0.42
EPS:
-24.2853
Net Cash Flow:
$-85.33M
1W Performance:
+32.47%
1M Performance:
+11.84%
6M Performance:
-45.25%
1Y Performance:
-26.30%
1-Day Range:
$9.3883
$10.83
1-Week Range:
$7.7822
$10.83
52-Week Range:
$3.76
$46.80
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Name
Aligos Therapeutics Inc
Sector
Industry
Phone
(800) 466-6059
Address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
10.20 | 60.96M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Initiated | H.C. Wainwright | Buy |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-23-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-09-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Resumed | Piper Sandler | Overweight |
| Nov-10-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Initiated | JP Morgan | Overweight |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Aligos Therapeutics Inc Stock (ALGS) Latest News
Aligos Therapeutics appoints Ramon Polo as head of global regulatory affairs - TipRanks
Aligos Therapeutics appoints Ramón Polo as head of global regulatory - Investing.com
Aligos Therapeutics Appoints Ramón Polo as Senior VP, Head of Global Regulatory Affairs - Quiver Quantitative
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs - The Globe and Mail
Former J&J COVID-19 Vaccine Regulatory Leader Joins Aligos Therapeutics as Global Regulatory Head - Stock Titan
Is Aligos Therapeutics Inc. forming a bottoming baseQuarterly Market Summary & Technical Pattern Recognition Alerts - Newser
Aligos Therapeutics Inc. stock outlook for YEARJuly 2025 Spike Watch & Accurate Intraday Trade Tips - Newser
Sector ETF performance correlation with Aligos Therapeutics Inc.Weekly Risk Summary & Community Verified Trade Signals - Newser
Will Aligos Therapeutics Inc. continue its uptrendWeekly Trend Summary & Fast Gaining Stock Strategy Reports - Newser
Is Aligos Therapeutics Inc. meeting your algorithmic filter criteria2025 Short Interest & Advanced Swing Trade Entry Plans - Newser
What data driven models say about Aligos Therapeutics Inc.’s future2025 Trading Recap & Capital Efficiency Focused Ideas - Newser
Aligos Therapeutics Inc. recovery potential after sell offJuly 2025 Trade Ideas & Risk Adjusted Buy/Sell Alerts - Newser
Can volume confirm reversal in Aligos Therapeutics Inc.Bond Market & Safe Capital Growth Tips - Newser
Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's What You Should Know - Zacks Investment Research
Will Aligos Therapeutics Inc. stock go up soonJuly 2025 Catalysts & Community Trade Idea Sharing Platform - Newser
Can you recover from losses in Aligos Therapeutics Inc.July 2025 Breakouts & Reliable Price Breakout Alerts - Newser
Aligos Therapeutics Inc. stock momentum explainedJuly 2025 Spike Watch & Safe Entry Point Identification - Newser
Will Aligos Therapeutics Inc. stock recover after recent drop2025 Biggest Moves & AI Driven Stock Reports - Newser
Real time breakdown of Aligos Therapeutics Inc. stock performanceEarnings Risk Report & AI Forecast Swing Trade Picks - Newser
Aligos Therapeutics stock gets Buy rating from H.C. Wainwright on HBV drug potential - Investing.com India
H.C. Wainwright Assumes Coverage of Aligos Therapeutics with Buy Rating - AInvest
Aligos Therapeutics assumed with a Buy at H.C. Wainwright - TipRanks
Aligos Therapeutics receives Buy rating and $50 price target from HC Wainwright & Co. - AInvest
Does Aligos Therapeutics Inc. show high probability of reboundEarnings Overview Report & Low Risk High Win Rate Picks - Newser
Smart tools for monitoring Aligos Therapeutics Inc.’s price actionJuly 2025 Summary & Proven Capital Preservation Tips - Newser
Will Aligos Therapeutics Inc. price bounce be sustainableAnalyst Upgrade & Advanced Swing Trade Entry Plans - Newser
How Efficient Is Aligos Therapeutics Inc. at Controlling Operating CostsJuly 2025 Big Picture & Real-Time Chart Breakout Alerts - Newser
Ranking Aligos Therapeutics Inc. among high performing stocks via tools - Newser
How to monitor Aligos Therapeutics Inc. with trend dashboardsWeekly Loss Report & Weekly Watchlist of Top Performers - Newser
Custom watchlist performance reports with Aligos Therapeutics Inc.July 2025 Sector Moves & Community Consensus Trade Alerts - Newser
Volatility clustering patterns for Aligos Therapeutics Inc.Weekly Profit Analysis & Fast Entry Momentum Alerts - Newser
News impact scoring models applied to Aligos Therapeutics Inc.2025 Institutional Moves & Daily Chart Pattern Signals - Newser
Is There Enough Volume to Lift Aligos Therapeutics Inc.Portfolio Update Report & Free Community Supported Trade Ideas - newsyoung.net
What is the dividend yield of Aligos Therapeutics Inc.2025 Trading Recap & Daily Risk Controlled Trade Plans - thegnnews.com
Is Aligos Therapeutics Inc. stock undervalued right nowWeekly Market Summary & AI Driven Price Forecasts - thegnnews.com
Using flow based indicators on Aligos Therapeutics Inc.Trade Volume Report & AI Driven Stock Reports - Newser
Using Bollinger Bands to evaluate Aligos Therapeutics Inc.July 2025 Opening Moves & Real-Time Buy Signal Alerts - Newser
Aligos Therapeutics Inc Stock (ALGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):